Average LDL-C reduction with lipid-lowering therapies (ESC/EAS): ■ Statins are the foundation: Moderate-intensity ≈ 30% High-intensity ≈ 50% ■ Statin + non-statin combinations markedly improve efficacy: High-intensity statin + ezetimibe ≈ 60% High-intensity statin + bempedoic acid ≈ 58% ■ PCSK9 inhibitors provide the largest incremental effect: PCSK9 mAb alone ≈ 60% With statins ± ezetimibe → 75–80% ■ Maximal LDL-C lowering (~85–86%) is achieved with quadruple therapy (high-intensity statin + ezetimibe + bempedoic acid + PCSK9 mAb). ■ Clinical implication: very-high-risk patients usually require early combination therapy to reach ESC LDL-C targets. #medical #cardiology #hearthealth #heart #fblifestyle
Dr. Usman's Cardiology Notes
Cardiology Notes: Clinical Cases including ECG, Echocardiography, Cath, and MOCK Exams to sharpen your cardiology data interpretation skills. Healthcare is stressful!!! Learning cardiology shouldn't be !!!